First Hawaiian Bank Trims Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

First Hawaiian Bank cut its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 57.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,476 shares of the medical research company’s stock after selling 6,071 shares during the period. First Hawaiian Bank’s holdings in Charles River Laboratories International were worth $826,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the company. Wellington Management Group LLP increased its position in shares of Charles River Laboratories International by 135,927.9% during the third quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock valued at $736,819,000 after acquiring an additional 3,738,018 shares during the last quarter. Allspring Global Investments Holdings LLC increased its position in shares of Charles River Laboratories International by 40.7% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,760,781 shares of the medical research company’s stock valued at $346,821,000 after acquiring an additional 509,163 shares during the last quarter. Marshall Wace LLP increased its position in shares of Charles River Laboratories International by 24.6% during the second quarter. Marshall Wace LLP now owns 825,905 shares of the medical research company’s stock valued at $170,615,000 after acquiring an additional 163,056 shares during the last quarter. 1832 Asset Management L.P. acquired a new stake in shares of Charles River Laboratories International during the second quarter valued at about $33,053,000. Finally, Earnest Partners LLC grew its holdings in shares of Charles River Laboratories International by 12.4% in the second quarter. Earnest Partners LLC now owns 1,004,486 shares of the medical research company’s stock valued at $207,507,000 after purchasing an additional 110,725 shares in the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Charles River Laboratories International

In related news, Director Richard F. Wallman sold 6,621 shares of the company’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the sale, the director now owns 12,386 shares in the company, valued at $2,676,862.32. This represents a 34.83 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.30% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on CRL shares. Bank of America dropped their price objective on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a report on Friday, December 13th. TD Cowen lifted their price objective on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a report on Monday, November 11th. Robert W. Baird dropped their price objective on shares of Charles River Laboratories International from $191.00 to $190.00 and set a “neutral” rating for the company in a report on Friday, September 20th. CLSA cut shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price objective for the company. in a report on Monday, November 18th. Finally, UBS Group lifted their price objective on shares of Charles River Laboratories International from $240.00 to $250.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Three equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $214.00.

Charles River Laboratories International Stock Down 1.0 %

Shares of NYSE:CRL opened at $186.07 on Friday. The company has a market capitalization of $9.51 billion, a PE ratio of 23.29, a P/E/G ratio of 5.00 and a beta of 1.38. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61. Charles River Laboratories International, Inc. has a twelve month low of $176.48 and a twelve month high of $275.00. The firm has a 50 day simple moving average of $193.32 and a 200-day simple moving average of $199.71.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.43 by $0.16. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $975.99 million. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The company’s revenue was down 1.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.72 EPS. On average, equities analysts predict that Charles River Laboratories International, Inc. will post 10.18 EPS for the current fiscal year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).